ASCO 2019 | IMpassion130: immunotherapy for TNBC

Peter Schmid

Peter Schmid, MD, PhD, FRCP, of the Barts Cancer Institute, London, UK, discusses the treatment of triple-negative breast cancer (TNBC) and the introduction of immunotherapy in the disease, specifically mentioning the IMpassion130 trial (NCT02425891). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video